Baylor Scott & White Annette C. and Harold C. Simmons Transplant Institute is a leader in the field of transplant in numerous areas. Today, they are responsible for one more: Baylor Scott & White Health has the largest team of female abdominal transplant surgeons in the United States.
Baylor Scott & White Research Institute was recently selected as one of only seven sites in the nation to participate in the landmark feasibility study of the Carmat Total Artificial Heart (TAH) for transplant-eligible patients in severe, end-stage heart failure. It is also the only site to offer the FDA-approved TAH in the region.
Cardiovascular disease is a known determinant of morbidity and mortality in patients undergoing kidney transplantation, which is the commonly chosen treatment for patients with end-stage kidney disease. Researchers for this study sought to examine the rate of major cardiovascular adverse events (MACEs), in the context of an aging transplant population on waitlists, higher diabetic populations and increasing dialysis pre-transplantation, specifically for the perioperative kidney transplantation period.
For decades, transplant programs have performed liver transplants on patients with alcohol-related cirrhosis. Most of these patients have not used alcohol for many months, if not years. However, a small subset of patients—many of them younger and female—are presenting with acute alcoholic hepatitis. Historically, liver transplants have not been performed on these patients.
